Esperion Therapeutics, Inc.
ESPR
$3.14
-$0.01-0.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 61.13% | 21.31% | 2.83% | -3.48% | 12.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.13% | 21.31% | 2.83% | -3.48% | 12.99% |
| Cost of Revenue | 23.70% | 54.20% | 60.02% | 33.48% | 23.34% |
| Gross Profit | 101.98% | 3.95% | -29.85% | -26.99% | 3.50% |
| SG&A Expenses | 1.12% | 1.66% | -6.00% | -3.29% | 6.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.33% | 23.37% | 19.42% | 11.26% | 13.28% |
| Operating Income | 289.65% | 10.79% | -278.55% | -816.39% | -15.20% |
| Income Before Tax | 96.36% | 59.72% | -21.97% | -5.61% | -77.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 95.16% | 56.17% | -21.97% | -5.61% | -77.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 95.16% | 56.17% | -21.97% | -5.61% | -77.12% |
| EBIT | 289.65% | 10.79% | -278.55% | -816.39% | -15.20% |
| EBITDA | 290.31% | 10.78% | -277.06% | -803.16% | -15.37% |
| EPS Basic | 92.51% | 27.37% | 13.62% | 36.57% | 17.77% |
| Normalized Basic EPS | 89.69% | -353.08% | -55.84% | 5.93% | 47.78% |
| EPS Diluted | 86.99% | 17.13% | 16.94% | 38.40% | 19.83% |
| Normalized Diluted EPS | 80.71% | -958.11% | -39.84% | 12.06% | 49.79% |
| Average Basic Shares Outstanding | 14.30% | 11.03% | 18.72% | 34.66% | 54.23% |
| Average Diluted Shares Outstanding | 20.48% | 14.31% | 15.20% | 30.11% | 48.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |